BrainCool AB AI Stock Analysis
Want to see SE:BRAIN full AI Analyst Report?
BrainCool AB (BRAIN) AI Stock Analysis
BrainCool AB
(Nasdaq OMX AB:BRAIN)
The score is held back primarily by weak financial performance—negative gross profit, heavy cash burn, and ongoing losses—despite a low-debt balance sheet. Technicals are a clear positive with price above major moving averages and positive momentum indicators, while valuation remains constrained by unprofitability and the absence of a dividend.
BrainCool AB (BRAIN) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 473.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 451.22K
- Price to Earnings (P/E)
- -13.0
- Beta (1Y)
- 0.41
- Revenue Growth
- 0.04%
- EPS Growth
- 34.45%
- Country
- Sweden
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
BrainCool AB Business Overview & Revenue Model
Company Description
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company cat...
How the Company Makes Money
BrainCool makes money primarily by selling and/or leasing its temperature management systems to hospitals and other healthcare providers and by generating recurring revenue from disposable consumables and accessories used together with those systems...
BrainCool AB Financial Statement Overview
Summary
Revenue is growing strongly, but the company remains deeply unprofitable with negative gross profit and very weak margins, alongside sustained negative operating and free cash flow. The balance sheet is a relative positive with zero reported debt and sizable equity, but negative ROE and ongoing cash burn keep overall financial quality speculative.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 43.63M | 36.21M | 39.96M | 23.23M | 17.59M | 9.26M |
| Gross Profit | -37.10M | -40.88M | 13.13M | 12.12M | -46.16M | -48.93M |
| EBITDA | -26.43M | -29.99M | -34.03M | -49.86M | -35.07M | -32.16M |
| Net Income | -31.59M | -37.05M | -44.04M | -61.28M | -45.61M | -38.75M |
Balance Sheet | ||||||
| Total Assets | 167.55M | 192.38M | 162.04M | 133.28M | 133.67M | 99.35M |
| Cash, Cash Equivalents and Short-Term Investments | 36.28M | 39.57M | 31.40M | 25.06M | 41.21M | 13.58M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 35.00M |
| Total Liabilities | 14.85M | 16.58M | 16.11M | 21.54M | 17.44M | 54.12M |
| Stockholders Equity | 152.71M | 175.80M | 145.93M | 111.74M | 116.23M | 45.23M |
Cash Flow | ||||||
| Free Cash Flow | -53.05M | -56.49M | -70.20M | -67.23M | -53.67M | -35.06M |
| Operating Cash Flow | -51.02M | -52.68M | -62.64M | -61.16M | -46.27M | -24.25M |
| Investing Cash Flow | -4.77M | -6.54M | -7.57M | -6.17M | -7.59M | -10.82M |
| Financing Cash Flow | 85.23M | 67.33M | 76.80M | 50.93M | 81.28M | 36.39M |
BrainCool AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BRAIN, the sentiment is Positive. The current price of 1.20 is above the 20-day moving average (MA) of 1.07, above the 50-day MA of 1.06, and above the 200-day MA of 0.79, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 68.13 is Neutral, neither overbought nor oversold. The STOCH value of 95.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BRAIN.
BrainCool AB Peers Comparison
Overall Rating
SE:GETI.B67Neutral
SE:XVIVO64Neutral
SE:PAX57Neutral
SE:BRAIN54Neutral
SE:OSSD52Neutral
SE:SEDANA49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | SEK 75.53B | 26.69 | 9.13% | 1.71% | -3.90% | 37.73% | |
| 64Neutral | SEK 6.17B | 47.92 | 5.89% | ― | 17.83% | 330.94% | |
| 57Neutral | SEK 1.55B | -306.14 | -1.22% | ― | 34.05% | -144.96% | |
| 54Neutral | SEK 473.85M | -12.99 | -19.29% | ― | 0.04% | 34.45% | |
| 52Neutral | SEK 368.38M | -7.36 | ― | ― | -11.89% | -11.85% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 921.85M | -26.71 | -3.88% | ― | 0.42% | 15.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BRAIN | BrainCool AB | 1.20 | 0.61 | 105.13% | |
| SE:GETI.B | Getinge AB (UK) | 277.30 | 74.58 | 36.79% | |
| SE:PAX | Paxman AB | 66.80 | 4.80 | 7.74% | |
| SE:XVIVO | Xvivo Perfusion AB | 196.00 | 31.00 | 18.79% | |
| SE:SEDANA | Sedana Medical AB | 9.28 | -0.33 | -3.43% | |
| SE:OSSD | OssDsign AB | 3.33 | -7.41 | -68.99% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
